Bergen, Norway, 4 February 2025: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), can announce that chemistry with improved sensitivity has been
successfully tested in Lifecare's CGM-sensor.
Reference is made to Lifecare's stock exchange announcement 14 January 2025,
regarding up to fivefold improvement in sensor chemistry sensitivity, with a
new generation of Lifecare's proprietary chemistry.
Lifecare's laboratory in Mainz, Germany, has now completed the first tests of
the improved chemistry in implants similar to those used in the company's
long-term studies. These implants have been subjected to laboratory testing.
Similar to the initial and very promising tests of the chemistry in macro-test
cells, the first analyses show promising responses after testing the chemistry
in miniaturized sensors. This contributes to our expectation that the
chemistry can lead to significantly improved sensor sensitivity. The actual
function of the implants in-vitro will be subject to ongoing testing, after
which the implants with improved sensor chemistry later will be subjected to
long-term studies in-vivo.
The sensor sensitivity defines the potential to detect small changes of
glucose levels and is an important performance parameter for CGM. The accuracy
of CGM's is commonly referred to based on Mean Absolute Relative Difference
(MARD), where a MARD lower than 10% indicates clinically acceptable accuracy.
In Q2 2023, data from Lifecare's Clinical Development Study LFC-SEN-001
confirmed that our CGM system had achieved a MARD of 9,7%. The improved
chemistry sensitivity can impact the MARD, however this is subject to further
testing.
In a product perspective the most prominent benefit of enhanced sensor
sensitivity is improvement of the sensor signal-to-noise ratio. This leads to
improved data readings and enhanced sensor performance, as well as simplifying
algorithms and data processing efficiency.
- Any validation of the improved chemistry sensitivity represents a
confirmatory advance for our sensor technology. However, it is particularly
promising that the improved chemistry sensitivity now has been subject to
initial validation in a near-real-world test scenario. Lifecare's team of
researchers and developers continuously strives for improved precision and
quality in glucose monitoring to ensure better outcomes for patients with
diabetes, says Joacim Holter, Lifecare CEO.
About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42